
|Articles|February 1, 2001
CME: Offering mifepristone as an abortion option
While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug need to familiarize themselves with the research on its advantages and disadvantages.
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Phase 1 trial shows promise for triple-negative breast cancer vaccine
2
No evidence links menopause hormone therapy to dementia risk
3
Disrupted uterine scar healing may drive placenta accreta spectrum development
4
Planned early-term birth reduces preeclampsia risk
5











